Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7) : an exploratory analysis of a randomised controlled trial - The Lancet
▻https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/abstract
(Variant britannique)
L’étude est analysée dans un éditorial de la même revue, qui met en avant deux constatations occultées dans le résumé de ladite étude :
1) le vaccin pourrait être nettement moins efficace contre les formes #asymptomatiques du variant britannique (nombre de malades trop faible pour tirer des conclusions fermes)
2) les intervalles de confiance, trop larges, ne permettent pas de tirer des conclusions solides concernant les formes symptomatiques.
Although based on small case numbers, a larger difference in efficacy was observed for #SARS-CoV-2 infections with no or unreported symptoms (28·9% [–77·1 to 71·4] for B.1.1.7 and 69·7% [33·0 to 86·3] for other #variants).
[...]
Given the wide CIs in these exploratory analyses, no firm conclusions can be drawn on the precise clinical efficacy against the B.1.1.7 variant and, importantly, how this efficacy compares with efficacy against the original circulating variants. However, the results point towards lower efficacy, which also seems consistent with the nine-times reduction in neutralising activity against the B.1.1.7 #variant compared with non-B.1.1.7 variants in the serum samples from vaccinees in this study.
